Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma

Clinical trial NCT07644897 · RECRUITING

Trial details

NCT number: NCT07644897
Sponsor: Sun Yat-sen University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma Immune-related Adverse Event Immune Checkpoint Inhibitor

Start date: 2023-05-30
Primary completion: 2027-05-30
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.